Aminoglycosides in Early Sepsis (AGES): A Randomized Pragmatic Clinical Trial Comparing Gentamicin and Narrow Spectrum Betalactams to Broad Spectrum Betalactams as Empirical Treatment in Patients With Suspected Sepsis

Norwegian guidelines for empirical antibiotic therapy in suspected community acquired sepsis recommend the combination of narrow spectrum betalactam and aminoglycoside as the first choice, but broad spectrum betalactams are considered equally appropriate, effective, and safe. However, fear of renal complications due to gentamicin and concern for lacking evidence for efficiency commonly leads to the use of broad spectrum betalactam therapy, a larger driver of antibiotic resistance.
In patients with suspected community acquired sepsis, the investigators hypothesize that empirical combination therapy with narrow spectrum betalactams and aminoglycosides is safe and non-inferior to empirical therapy with broad spectrum betalactams. More specifically, the investigators hypothesize that the proportion of patients with acute kidney injury or death will be similar between these two treatment groups. Furthermore, the investigators hypothesize that the aminoglycoside-based regimen has lesser impact on the gut microbiome. Antimicrobial resistance is one of the most urgent health threats of our time, and Norwegian hospitals were required but failed to reduce the use of broad-spectrum antibiotics with 30% by the end of 2020. In this context, novel initiatives aiming at reducing use of antibiotics are direly needed.

Start Date01 Jun 2025

Sponsor / Collaborator

Akershus Universitetssykehus HF

[+1]

NCT06690905

/ RecruitingPhase 4IIT

Evaluation of the Achievement of a Pharmacodynamic Target of Piperacillin-Tazobactam for the Population with Obesity: an Open Randomized Controlled Feasibility Study

This study aims to evaluate the feasibility of an open randomized controlled study which would assess the proportion patients with obesity who will have a favorable pharmacodynamic parameter (i.e. fT> 100% MIC) after 24 hours of piperacillin-tazobactam administered as a prolonged intermittent infusion compared to a standard infusion.

Start Date26 Feb 2025

Sponsor / Collaborator-

TCTR20240917008

/ Not yet recruitingPhase 3IIT

A comparison of clinical response of vancomycin plus piperacillin/tazobactam and vancomycin plus meropenem empiric therapy in non-critically ill hemodialysis patients with suspected central line-associated bloodstream infections: an open-label, randomized controlled trial

Start Date01 Oct 2024

Sponsor / Collaborator-

100 Clinical Results associated with Piperacillin Sodium/Tazobactam Sodium

100 Translational Medicine associated with Piperacillin Sodium/Tazobactam Sodium

100 Patents (Medical) associated with Piperacillin Sodium/Tazobactam Sodium

5,030

Literatures (Medical) associated with Piperacillin Sodium/Tazobactam Sodium

01 Dec 2025·MOLECULAR BIOLOGY REPORTS

Green synthesis of silver nanoparticles using Acroptilon repens aqueous extract and their antibacterial efficacy against multidrug-resistant Acinetobacter baumannii

Article

Author: Shahbazi, Shahla ; Shamsoddini, Seyed Mahdi ; Karizi, Shohreh Zare ; Davoudi, Mahdieh

BACKGROUND:

Acinetobacter baumannii is a critical pathogen associated with hospital-acquired infections, particularly in burn and intensive care unit (ICU) patients, and is notorious for its high level of antibiotic resistance. This study aims to evaluate the antibacterial potential of silver nanoparticles (AgNPs) synthesized using Acroptilon repens extract as a promising alternative treatment for combating multidrug-resistant A. baumannii.

METHODS AND RESULTS:

Twelve clinical isolates of A. baumannii were identified through biochemical testing. Antibiotic susceptibility testing using the Kirby-Bauer disk diffusion method revealed universal resistance to ceftazidime, amikacin, imipenem, gentamicin, ciprofloxacin, and piperacillin-tazobactam, while all isolates remained sensitive to colistin (p ≤ 0.05). AgNPs were synthesized using A. repens extract and characterized through transmission electron microscopy (TEM), scanning electron microscopy (SEM), particle size analysis (PSA), UV-Vis spectroscopy, X-ray diffraction (XRD), and Fourier-transform infrared spectroscopy (FT-IR). TEM analysis showed that the AgNPs had a spherical morphology with an average particle size of approximately 30 nm, while SEM confirmed their spherical shape and size distribution, ranging from 10 to 130 nm, with a mean size of 38.89 nm. UV-Vis spectroscopy confirmed the successful formation of AgNPs, indicated by a distinct broad absorption peak between 400 and 480 nm. XRD analysis validated the crystalline nature of the nanoparticles, with characteristic peaks at 2θ values of 38.21°, 46.28°, 64.57°, and 77.49°, corresponding to the (111), (200), (220), and (311) planes of face-centered cubic (fcc) silver. Antibacterial activity was evaluated by determining the minimum inhibitory concentration (MIC), which ranged from 50 to 400 µg/mL. The highest inhibitory activity was observed at 400 µg/mL. Gene expression analysis using quantitative real-time PCR (qRT-PCR) demonstrated downregulation of the oprD and carO porin genes following AgNP treatment. However, these reductions were not statistically significant (p = 0.302 and p = 0.198, respectively).

CONCLUSIONS:

AgNPs synthesized from A. repens demonstrated strong antibacterial activity against multidrug-resistant A. baumannii. While downregulation of porin genes was observed, further investigation is required to elucidate the underlying mechanisms of action and assess their potential clinical applications. These findings support the potential of AgNPs as an alternative therapeutic strategy for addressing A. baumannii infections resistant to conventional antibiotics.

01 May 2025·Journal of Global Antimicrobial Resistance

First report of an Enterobacter cloacae ST837 resistant to cefiderocol co-harbouring blaIMP-19 and mcr-4.3 resistance genes in Italy

Article

Author: Secci, Benedetta ; Foschi, Claudio ; Menozzi, Ilaria ; Ambretti, Simone ; Scaltriti, Erika ; Lazzarotto, Tiziana ; Dodi, Alessandra ; Pongolini, Stefano

OBJECTIVE:

To describe the molecular characterisation of an Enterobacter cloacae strain resistant to cefiderocol and co-harbouring bla_IMP-19 and mcr-4.3 resistance genes METHODS: The strain was isolated from the rectal swab of a 77-year-old woman during screening for the detection of patients colonised by carbapenemase-producing Enterobacterales (CPE) in Bologna (Italy). The strain was identified at species level by MALDI-TOF mass spectrometry and the presence of active-on-imipenem (IMP) carbapenemase was confirmed both by a phenotypic immunochromatographic method, and by a rapid commercial nucleic acid amplification test. The strain underwent antimicrobial susceptibility testing and its genome was fully characterised to assess (i) the multilocus sequence type, (ii) the presence of antimicrobial resistance (AMR) genes, and (iii) the presence of virulence genes coupled with mobile genetic elements.

RESULTS:

Multilocus sequence typing identified the strain as ST837. A plasmid of 60 691 bp, very similar to the MW574937 plasmid of Escherichia coli, was identified and carried the following AMR genes: aac(6')-II, bla_BEL-1, bla_IMP-19, msr(E), mph(E), and sul1. This plasmid harboured several tra genes (traB, traC, traD, traG, traI, traJ, traKtraL, and traM) of the transfer operon of the E. coli conjugative F plasmid. Other AMR genes were located in the chromosome (bla_CMH-3 and fosA) or in other plasmids (bla_SHV-12 and mcr-4.3). The strain showed resistance to many β-lactams in vitro, including cefiderocol, whereas, despite the presence of the mcr-4.3 gene, it was susceptible to colistin.

CONCLUSIONS:

Further studies are needed to better evaluate the origin of this strain and monitor the presence of Gram-negative bacilli with a similar molecular structure in our area.

01 Apr 2025·AMERICAN JOURNAL OF EMERGENCY MEDICINE

PEN-FAST-ED: Utilizing the PEN-FAST decision tool to guide antibiotic prescribing in the emergency department

Article

Author: Kisgen, Jamie ; Langley, David ; Lund, Jeremy ; Tran, Kimberly ; Sealy, Chloe

BACKGROUND:

Patient-reported penicillin allergies are frequently encountered in the emergency department (ED), which often lead to non-beta-lactam antibiotic use despite beta-lactams' place as first-line therapy in most bacterial infections. The PEN-FAST clinical decision tool was developed and validated to identify patients with a low risk of true penicillin allergies that do not require formal skin testing for rechallenging. The tool consists of four questions that add up to a total score ranging from 0 to 5. Scores of 0-2 are associated with low risk of true penicillin allergy (<5% risk of true reaction); scores of 3 with moderate risk (<20% risk); and scores of 4-5 with high risk (50% risk). The purpose of our study was to determine the safety and efficacy of our facility's implementation of pharmacist utilization of the PEN-FAST screening tool to assess purported penicillin allergies and rechallenge low to moderate risk patients in the ED.

METHODS:

This was a single-center, prospective, observational cohort study conducted from October 2023 to March 2024. Adult ED patients with a documented penicillin allergy with an order for aztreonam, levofloxacin, clindamycin, or a consult for pharmacy to assist with antibiotic selection were included. Patients were excluded if the order or consult was placed by a non-ED physician, no penicillin allergy was documented, the patient had previously tolerated a penicillin or cephalosporin per chart review, was unable to participate in the interview, or the completion of the assessment would delay patient care. The primary outcome was the percent of patients with a PEN-FAST score of 0-2 who tolerated a beta-lactam antibiotic after pharmacist intervention. Secondary safety and logistical outcomes included the incidence of immune-mediated reactions within one hour of beta-lactam administration, timing of the assessment, and antibiotic selection in transitions of care.

RESULTS:

Of the 361 patients screened, 100 patients were included. There were 61% of patients who had a PEN-FAST score of 0-2, 30% had a score of 3, and 9% had a score of 4-5. For the primary outcome, all 52 (100%) patients with a PEN-FAST score of 0-2 who were rechallenged tolerated a beta-lactam antibiotic in the ED. For secondary outcomes, 6 patients with PEN-FAST score of 3 were rechallenged and tolerated a beta-lactam. There were 0 incidences of any immune-mediated reactions within one hour of beta-lactam administration. The median time from initial order placement to change in therapy and to antibiotic administration was 17 min and 41 min, respectively. Of those rechallenged, 13 of 14 discharged (93%) and 39 of 44 admitted patients (89%) were continued on beta-lactam antibiotics.

CONCLUSION:

In this prospective, observational study, administration of beta-lactam antibiotics to ED patients with previously reported penicillin allergies and a PEN-FAST score less than 3 did not result in any immune-mediated reactions. The PEN-FAST decision tool was able to safely identify and risk-stratify eligible patients for beta-lactam rechallenge in the ED.

News (Medical) associated with Piperacillin Sodium/Tazobactam Sodium

18 Dec 2024

·www.businesswire.com

Valink Therapeutics Appoints Biopharmaceutical Veteran Martin D. Williams as Chair of the Board of Directors and Names Scientific Advisory Board

BOSTON--( BUSINESS WIRE )--Valink Therapeutics, a biopharmaceutical company focused on discovering and developing innovative bispecific antibody-drug conjugates (bsADCs) to transform the treatment of cancer and other diseases, has appointed Martin D. Williams as Chair of its Board of Directors. The company also named its Scientific Advisory Board, which assembles experts in the discovery, development, manufacture and commercialization of ADCs and bispecific therapeutics. “ We are thrilled to welcome Martin, whose expertise in strategy, development and partnering, and track record of leading multiple U.S. biopharmaceutical companies, will be instrumental to the next stages of Valink. He brings deep experience advancing a wide range of therapeutics from early development through regulatory approval and commercialization and developing industry partnerships that move promising medicines closer to patients. Martin’s career journey, which began in the UK before his move to the U.S. over 30 years ago, mirrors Valink’s roots as a University of Oxford spinout based in the U.S., with a strong UK presence,” said Arne Scheu, DPhil, Co-founder and Chief Executive Officer of Valink. “ Furthermore, I am excited to announce our Scientific Advisory Board, which brings together a distinguished group of advisors who have been at the forefront of ADC and bispecific innovation and development.” Mr. Williams brings to Valink more than 35 years of experience in the global biopharmaceutical business, having closed more than $5 billion worth of corporate transactions, including numerous partnerships, M&A, and public and private financings. He recently served as Chief Executive Officer of Caraway Therapeutics, a venture-backed company developing therapeutics to modulate lysosomal function for neurodegenerative and rare diseases, through the company’s acquisition by Merck & Co. at the end of 2023. Previously, he was President and Chief Executive Officer of Tokai Pharmaceuticals, a clinical-stage oncology company; Chief Business Officer at Dicerna Pharmaceuticals, a leading RNAi company with programs in oncology; and Chief Business Officer and Senior Vice President for commercial and business development at Synta Pharmaceuticals, a clinical-stage public company focused on oncology and inflammation. Earlier in his career, he held various leadership positions and directed the development, commercialization and launch of several flagship brands for GSK, Hoffmann-La Roche and Lederle/Wyeth (now Pfizer), including GSK’s blockbusters Zantac® and Zofran®; Hoffmann La-Roche’s Xenical®; and Lederle/Wyeth’s global anti-infective portfolio, including Zosyn®/Tazocin®. He holds an MBA from Harvard Business School and an MS from the University of Manchester, UK. “ Valink has developed a compelling approach to realizing the unmet potential of ADCs to improve outcomes for patients with cancer and other diseases, which has been restricted by dose-limiting toxicities and the range of suitable targets. Their technology addresses a significant challenge to ADC innovation by enabling rapid and cost-effective generation and screening of bispecific ADCs, unlocking a vast range of target synergy and potentially bringing previously undruggable space within reach,” said Mr. Williams. “ I am excited to work closely with the Valink executive team and Board as the company builds on its discoveries and pursues its clinical aspirations.” Valink also announced the formation of its Scientific Advisory Board, initially consisting of: Sonia Quaratino, MD, PhD is Executive Vice President and Chief Medical Officer at Innate Pharma, a clinical-stage biotech utilizing monoclonal antibodies, multi-specific NK cell engagers and ADCs to develop immunotherapies for cancer. Her career spans over 25 years in basic research, clinical development and translational medicine across academia, biotech and global pharmaceuticals. She has held numerous leadership positions, including serving as CMO at Kymab (until its acquisition by Sanofi) and Georgiamune Inc, and was Professor of Immunology at the University of Southampton. Marc Damelin, PhD is Chief Scientific Officer at Alphina Therapeutics and an expert in oncology drug discovery and development. Previously he served as VP and Head of Biology at Mersana Therapeutics, a clinical-stage biotech developing ADCs to treat cancer. Prior to that he worked for a decade in ADC discovery and development in Pfizer's Oncology Research Unit. Robert Lutz, PhD , Chief Scientific Officer at leading ADC company Iksuda Therapeutics, is a recognized expert in ADC discovery and development. As VP of Translational R&D at ImmunoGen, he was responsible for bringing eight ADC product candidates into development and was the research lead for Kadcyla®, the first ADC to be approved for solid tumor indications. Antoine Awad , Principal Executive Officer of Synlogic, has extensive experience in CMC, bispecific drug development and partnerships. Prior to Synlogic, he held leadership positions at various biotechs, including Merrimack Pharmaceuticals, where he led CMC development, manufacturing and approval of ONIVYDE® for treatment of advanced pancreatic cancer and transitioned to Ipsen Bioscience to lead global commercial manufacturing of ONIVYDE®. Mihriban Tuna, PhD is Chief Executive Officer of Immutrin and Entrepreneur-in-Residence at Cambridge Innovation Capital, a leading UK-based venture company focused on deep tech and life sciences. She previously served as Chief Scientific Officer at Adaptate Biotherapeutics (acquired by Takeda) and SVP, Drug Discovery at F-star Therapeutics, and was an early employee at Domantis Ltd. (acquired by GSK). Alexey A. Lugovskoy, PhD is President and Chief Executive Officer of Diagonal Therapeutics, Entrepreneur-in-Residence at Atlas Ventures and Associate Editor of mAbs . He formerly served as Chief Operating Officer at Dragonfly, Chief Development Officer at Morphic, Vice President of Therapeutics at Merrimack Pharmaceuticals and Associate Director of Drug Discovery at Biogen. He joined Valink’s Board of Directors in 2023, and this additional appointment highlights a close collaboration between the Scientific Advisory Board, Board of Directors and leadership team. About Valink Therapeutics Valink Therapeutics Inc. is a biopharmaceutical company focused on the discovery and development of first-in-class bispecific antibody-drug conjugates (bsADCs) to transform the treatment of cancer and other diseases. Valink’s technology platform utilizes a modular assembly approach to rapidly generate bsADCs with therapeutic potential, testing drugs at unparalleled scale and speed to improve on the payload delivery and selectivity of conventional ADCs. The company is based in Boston, Massachusetts and has research and development operations in London, UK. For more information, visit the company’s website at www.valinktx.com or contact the company at connect@valinktx.com .

Executive ChangeADCAcquisitionDrug Approval

13 May 2024

·www.sciencedaily.com

Commonly used antibiotic brings more complications, death in the sickest patients

Treatment with the commonly used antibiotic piperacillin/tazobactam was associated with a 5 percent increase in 90-day mortality, more days on a ventilator, and more time with organ failure for patients with sepsis, finds a new study. In emergency rooms and intensive care units across the country, clinicians make split-second decisions about which antibiotics to give a patient when a life-threatening infection is suspected. A new U-M study reveals that these decisions may have unintended consequences for patient outcomes. Beginning in 2015, a 15-month national shortage of a commonly prescribed antibiotic, piperacillin/tazobactam, known by the brand name Zosyn, provided a unique opportunity to compare rates of death in hospitalized patients with sepsis who were administered two different types of antibiotics -- one that spares the gut microbiome and one that profoundly alters it. Piperacillin/tazobactam is a broad-spectrum antibiotic that is commonly administered for sepsis, a life-threatening complication from infection. In its absence, clinicians commonly instead use another antibiotic, cefepime, which has similar activity against common sepsis pathogens but, unlike piperacillin/tazobactam, has minimal effects on anaerobic gut bacteria. "We saw this Zosyn shortage as a one-of-a-kind opportunity to ask whether this antibiotic, which we know depletes the gut of anaerobic bacteria, makes a difference in terms of patient outcomes," said Robert Dickson, M.D. of the Department of Medicine's Division of Pulmonary & Critical Care Medicine and Deputy Director of the Weil Institute for Critical Care Research & Innovation. In health, the gut microbiome is largely populated by anaerobic bacteria that rarely cause disease. Prior work by the study team has revealed that even a single dose of piperacillin/tazobactam kills most of these anaerobic gut bacteria, which play important roles in the body's metabolism, immunity, and prevention of infections. Dickson, Rishi Chanderraj, M.D. of the Division of Infectious Disease, Michael Sjoding, M.D. of the Division of Pulmonary & Critical Care Medicine and their multidisciplinary team at U-M and the VA Ann Arbor used patient record data to look at outcomes in 7,569 patients. The team compared 4,523 patients who were treated were piperacillin/tazobactam with 3,046 patients who received cefepime. They found marked differences: treatment with piperacillin-tazobactam was associated with a 5 percent increase in 90-day mortality, more days on a ventilator, and more time with organ failure. "These are powerful antibiotics that are administered to patients every day in every hospital nationwide," said Chanderraj. "Clinicians use them because they are trying to treat every possible pathogen that might be causing their patients' illness. But our results suggest that their effects on the microbiome might also have important effects on patient outcomes." The study builds on previous work by the study team that suggested critically ill patients may do worse when given antibiotics that deplete the gut of anaerobes. They have also seen similar effects when studying animal models. "Our prior work suggested that there might be harm with piperacillin/tazobactam, but it was an observational study that had some limitations," said Sjoding, the study's senior author. "That's why the drug shortage was such an amazing opportunity. It created an almost perfect natural experiment that let us test the difference between these two drugs on patient outcomes in a very rigorous manner." A recent clinical trial pitted these two antibiotics against each other and compared side effects and mortality after two weeks. That trial did not find any differences in the short term -- a finding that the U-M team also observed in their analysis. "When we looked at two-week outcomes in our study, we didn't find differences either," said Chanderraj. "But the differences at three months were dramatic." Overall, the new findings suggest that treatment with piperacillin/tazobactam instead of cefepime may contribute to one additional death per every 20 septic patients treated. "A 5% mortality difference has enormous implications because sepsis is so common," said Dickson. "Every day, thousands of clinicians are deciding which of these drugs to use in septic patients." Physicians should give more thought about whether anti-anerobic antibiotics are warranted before prescribing them, added Chanderraj. "We need to think about antibiotics like chemotherapy. In the right context, treatment can be lifesaving, but in the wrong context, it can be quite harmful."

Clinical Result

26 Apr 2024

·www.biospace.com

Bruker Further Enhances Clinical Microbiology & Infection Diagnostics Portfolio at ESCMID Global 2024 Conference

New MBT Pathfinder® IVD robot for automated MALDI Biotyper® target preparation New LiquidArray® MTB-XDR panel for simultaneous detection of M. tuberculosis complex bacteria, and their resistances to five WHO-recommended second-line drugs against multidrug-resistant tuberculosis Pending ELITech acquisition has received all regulatory clearances; closing now expected in the second quarter of 2024 BARCELONA, Spain--(BUSINESS WIRE)-- At the ESCMID Global 2024 conference, Bruker is enhancing its innovative diagnostic solutions in microbial identification, antimicrobial susceptibility testing (AST), early sepsis diagnostics, and other infectious disease assays. Simplifying microbiology and infectious disease diagnostics and workflows in the clinical laboratory is a key goal for Bruker in support of earlier and improved patient treatment decisions. This press release features multimedia. View the full release here: MBT Pathfinder® IVD with Feeder IVD (Photo: Business Wire) Microbial identification – towards automated sample preparation The latest MALDI Biotyper® workflow uses MBT Compass HT IVD software to increase throughput up to 600 samples per hour, and automated instrument tuning via IDealTune™. An optional workflow now offers semi-automated sample preparation via the MBT Pathfinder® IVD robot to avoid time-consuming, repetitive and error-prone manual tasks. Sepsis – when every minute counts When the correct antibiotic treatment for sepsis is given quickly, outcomes can improve dramatically. The IVD-CE MALDI Biotyper®, used in conjunction with the MBT Sepsityper® IVD Kit, can identify pathogens within 20 minutes from a positive blood culture bottle. Bruker offers additional clinical workflows for rapid functional antibiotic resistance testing, like the MBT STAR®-Carba IVD assay for the detection of carbapenemase activity. Antimicrobial susceptibility testing (AST) AST can indicate which antimicrobial regimen is effective for patients. Bruker’s UMIC® tests deliver accurate results for single antibiotics and combinations, and the MICRONAUT range offers AST of multiple antibiotics in a single test in a user-friendly workflow in compliance with CLSI/EUCAST recommendations. The UMIC® portfolio covers five antibiotics and combinations, namely colistin, piperacillin-tazobactam, vancomycin/teicoplanin, daptomycin and cefiderocol. In addition, Bruker is developing the new MBT-fAST assay for rapid AST of gram-negative bacteria from positive blood cultures directly on the MALDI Biotyper® platform. The MBT-fAST clinical studies are planned for the second half of 2024. Bruker also intends concurrent clinical studies for IVDR certification of lipid A-based colistin resistance detection. This and the on-going development of microbial species and subspecies differentiation based on lipid patterns will further enhance the value of the MALDI Biotyper® sirius system for clinical laboratories. The MALDI Biotyper® sirius stands out as the first MALDI-TOF mass spectrometry system for microbial identification that uses the negative ion mode for microbial lipid analysis. Currently, this feature is for Research Use Only (RUO), setting the stage for forthcoming clinical applications. Outbreak control The Bruker IR Biotyper® enables efficient microbial strain typing of bacteria and yeasts for real-time epidemiological surveillance for a range of disease-causing pathogens. During outbreak scenarios within hospitals, the IR Biotyper can help prevent the spread of hospital-acquired infections (HAI). The IR Biotyper® for hospital hygiene and infection control can be combined with the MALDI Biotyper® for microbial species identification. LiquidArray® – next-generation syndromic panels The new LiquidArray® Gastrointestinal syndromic panel facilitates the simultaneous detection of up to 26 pathogens responsible for gastroenteritis. This streamlines clinical decision-making by allowing the simultaneous analysis of multiple targets from a single sample. The rise of multidrug-resistant and extensively drug resistant M. tuberculosis strains has added complexity to TB diagnosis and treatment – and global travel is causing re-emergence in formerly low risk countries. Bruker’s new multiplex mycobacteria test LiquidArray® MTB-XDR VER 1.0, detects TB-causing bacteria of the M. tuberculosis complex and identifies resistance to five WHO-recommended second-line drugs. Dr. Wolfgang Pusch, President of the Bruker Microbiology & Infection Diagnostics division, commented: “Bruker is committed to innovation in routine microbiology and infectious disease testing. This includes nearly universal microbial identification with the MALDI Biotyper®, rapid blood culture analysis with the MBT Sepsityper® IVD Kit, early implementation of diagnostics for new antibiotics with our UMIC® portfolio, real-time epidemiological surveillance with the IR Biotyper®, and syndromic panels with our LiquidArray® assay portfolio.” Pending ELITechGroup Acquisition Regulatory Clearances As announced on February 28, 2024, Bruker Corporation has signed a Share Purchase Agreement to acquire ELITechGroup, excluding the ELITech clinical chemistry business. All regulatory clearances for this acquisition have now been received, and closing of the acquisition is expected during Q2 2024, subject to remaining closing conditions. About Bruker Corporation – Leader of the Post-Genomic Era (Nasdaq: BRKR) Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker’s high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity, and customer success in post-genomic life science molecular and cell biology research, in applied and biopharma applications, in microscopy and nanoanalysis, as well as in industrial and cleantech research, and next-gen semiconductor metrology in support of AI. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit . View source version on businesswire.com: Contacts Trade Press & Customer Contact: Philip Perry Senior Vice President, Marketing and Product Management Bruker Microbiology & Infection Diagnostics Division T: +49-172-313-7216 E: philip.perry@bruker.com Investor Contact: Justin Ward Sr. Director, Investor Relations & Corporate Development Bruker Corporation T: +1 (978) 313-5800 E: Investor.Relations@bruker.com Source: Bruker Corporation Smart Multimedia Gallery Photo MBT Pathfinder® IVD with Feeder IVD (Photo: Business Wire) Photo LiquidArray® MTB-XDR VER 1.0 (Photo: Business Wire) Logo View this news release and multimedia online at:

Acquisition

100 Deals associated with Piperacillin Sodium/Tazobactam Sodium

External Link

KEGG	Wiki	ATC	Drug Bank
-	Piperacillin Sodium/Tazobactam Sodium	J01CR05	-

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Pelvic Infection	United States	Wyeth Pharmaceuticals LLC	26 May 2020
Staphylococcal Skin Infections	Japan	Taiho Pharmaceutical Co., Ltd.	18 May 2017
Ulcer	Japan	Taiho Pharmaceutical Co., Ltd.	18 May 2017
Neutropenia	Japan	Taiho Pharmaceutical Co., Ltd.	26 Jun 2015
Abdominal Abscess	Japan	Taiho Pharmaceutical Co., Ltd.	28 Sep 2012
Cholangitis	Japan	Taiho Pharmaceutical Co., Ltd.	28 Sep 2012
Cholecystitis	Japan	Taiho Pharmaceutical Co., Ltd.	28 Sep 2012
Gynecological infection	Australia	Sandoz Pty Ltd.	10 Dec 2008
Lower Respiratory Tract Infections	Australia	Sandoz Pty Ltd.	10 Dec 2008
Sepsis	Australia	Sandoz Pty Ltd.	10 Dec 2008
Urinary Tract Infections	Australia	Sandoz Pty Ltd.	10 Dec 2008
Cystitis	Japan	Taiho Pharmaceutical Co., Ltd.	16 Jul 2008
Hemorrhagic Septicemia	Japan	Taiho Pharmaceutical Co., Ltd.	16 Jul 2008
Pyelonephritis	Japan	Taiho Pharmaceutical Co., Ltd.	16 Jul 2008
Endometritis	United States	Baxter Healthcare Corp.	06 May 2003
Community Acquired Pneumonia	United States	Baxter Healthcare Corp.	24 Feb 1998
Abscess	United States	Wyeth Pharmaceuticals LLC	22 Oct 1993
Appendicitis	United States	Wyeth Pharmaceuticals LLC	22 Oct 1993
Cellulitis	United States	Wyeth Pharmaceuticals LLC	22 Oct 1993
Diabetic Foot	United States	Wyeth Pharmaceuticals LLC	22 Oct 1993

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Febrile Neutropenia	Phase 3	United States	Wyeth AB	06 Sep 2002
Febrile Neutropenia	Phase 3	Canada	Wyeth AB	06 Sep 2002
Lymphoma	Phase 3	United States	Wyeth AB	06 Sep 2002
Lymphoma	Phase 3	Canada	Wyeth AB	06 Sep 2002
Hematologic Neoplasms	Phase 3	United States	Wyeth AB	04 Sep 2002
Hematologic Neoplasms	Phase 3	Canada	Wyeth AB	04 Sep 2002

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05753735 (CTgov)	Phase 2	Pancreatic Fistula	3	Piperacillin/Tazobactam (Standard Perioperative Antibiotics)	tcgfidxhla(gsfznhcaox) = wdacxiovqn lwvjufoxud (jzvixarlbj, qyupcrfoen - ogopqpgfsz) View more	-	24 Sep 2024
				Piperacillin/Tazobactam+Amoxicillin/ Clavulanic acid (Extended Antibiotic Prophylaxis)	oqynosiewl = riyqnuwfan dziplczpln (njrgnkbmrg, iqdrkhexpq - kdtvvrgrpn) View more
APAO2024	Not Applicable	-	-	Piperacillin-Tazobactam Eye Drops in Water for Injection (WFI)	wooznjysin(dyqvigluee) = grtbfssnnm opvzjsklyl (ahntkxgypi ) View more	Positive	22 Feb 2024
				Piperacillin-Tazobactam Eye Drops in Carboxymethyl Cellulose (CMC)	wooznjysin(dyqvigluee) = rkqqxomcxo opvzjsklyl (ahntkxgypi ) View more
NCT03289351 (CTgov)	Phase 4	Postoperative infection \| Appendicitis	162	ceftriaxone+metronidazole (2-drug Therapy)	ckhtltvnkw = qqrawfxjjm banlakxjjp (wjxzrbggvl, vfpzcryyys - exgeiqqois) View more	-	12 Jan 2024
				Piperacillin, Tazobactam Drug Combination (1-drug Therapy)	ckhtltvnkw = glggtxliqm banlakxjjp (wjxzrbggvl, fdbygjbckw - dvwwyzyviy) View more
NCT05102162 (CTgov)	Phase 4	Pneumonia	35	Meropenem+Piperacillin/Tazobactam+Cefepime (Continuous Antibiotic Dose Over 24 Hours Arm)	nyrjxtclyv = vshpenchgg zehwswlvtc (vqbwhhpvox, extwbphbxg - vshdcgqgpj) View more	-	12 Dec 2023
				Meropenem+Piperacillin/Tazobactam+Cefepime (Intermittent Antibiotic Dose Over 30 Minutes)	nyrjxtclyv = ulnxtedsjx zehwswlvtc (vqbwhhpvox, ijwduhnlsx - abvgbvygqw) View more
NCT03269994 (Pubmed)	Phase 3	-	778	Piperacillin-Tazobactam	ixgefcjudt(zylwhlhkwe) = bgrftanmgl oxbqxratpa (wjiyfgeelq )	-	20 Apr 2023
				Cefoxitin	ixgefcjudt(zylwhlhkwe) = exnbnnasjb oxbqxratpa (wjiyfgeelq )
NCT01694069 (PIPE-CF, CTgov)	Phase 4	Cystic Fibrosis	6	Piperacillin-tazobactam combination product (Intermittent Infusion Piperacillin-tazobactam)	cgcauorqlg(wesoxcyrxu) = rhvwuyebml xmrwnaozsw (uvrpllrxal, yscvsfmtcd - omdyobjuvv) View more	-	01 Feb 2022
				Piperacillin-tazobactam combination product (Continuous Infusion Piperacillin-tazobactam)	cgcauorqlg(wesoxcyrxu) = nkfingnygu xmrwnaozsw (uvrpllrxal, kyyeedxsqp - eztzrknmln) View more
NCT02991937 (CTgov)	Phase 4	Appendicitis	39	Piperacillin/Tazobactam (Medical Therapy)	eozcvssloy(lkvtfvdpbc) = qbkjiqipiy ethluarast (cxhglfhzye, xyyjstuqkz - hprzahcsdw) View more	-	21 Jan 2022
				Surgical Treatment+Piperacillin/Tazobactam (Surgical Intervention)	eozcvssloy(lkvtfvdpbc) = rvjuzcsxwl ethluarast (cxhglfhzye, cjasksipos - fzymglnpbt) View more
NCT03019965 (CTgov)	Not Applicable	Sepsis	426	Meropenem+Imipenem+Piperacillin+Tazobactam (Intermittent. Piperacillin/Tazobactam, Imipenem, Meropenem)	vshkcdbwpi = nxmlrzitun vpkjjbvbwk (ltjmcvrdbj, jbcpouzevt - sxtvvtfgtz) View more	-	05 Aug 2021
				Meropenem+Imipenem+Piperacillin+Tazobactam (Prolonged Infusion. Continuous Piperacillin/Tazobactam, Extended Imipenem, Extended Meropenem)	vshkcdbwpi = xkhzqhonyz vpkjjbvbwk (ltjmcvrdbj, zcpvncnqyc - syaqakwhuv) View more
EHA2021	Not Applicable	Hematopoietic stem cell transplantation	190	Aerobic antibiotics	zbybrofjrc(qcmjuoacsn) = yvghgakpue ilhzhbmqys (sgwhryfqpe )	-	09 Jun 2021
ATS2021	Not Applicable	Critical Illness	-	Piperacillin-Tazobactam	cpmxxwxytr(cqicvhcngy): adjusted odd ratio = 1.03 (95% CI, 0.83 - 1.27), P-Value = 0.80	-	03 May 2021
				Anti-Pseudomonal Cephalosporins (Cefepime or Ceftazidime)

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Piperacillin Sodium/Tazobactam Sodium

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation